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ABSTRACT
Introduction: Few studies have evaluated the 
contribution of individual symptoms and impair-
ments to the burden of multiple sclerosis (MS). 
This article reviews the contribution of walking 
impairment, fatigue, spasticity, depression, and 
pain, to quality of life (QOL) of the patient and 
economic burden of MS. Methods: Studies for 
inclusion were chosen from the literature that 
reported on QOL and costs in patients with 
MS, identified through PubMed searches (main 
search terms: “multiple sclerosis” combined 
with “quality of life,” “costs,” or “burden”). 
Articles were selected based on whether the 
analyses included evaluation of symptoms and 
impairments as contributory factors to QOL or 
costs. Results: Impaired mobility was ranked to 
be of high concern, and was suggested to be an 
important contributory factor to QOL, having 
a greater impact on physical components than 
mental components. Fatigue was associated with 
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QOL, with effects on both physical and mental 
components of QOL, independent of disability 
level. Depression was inversely associated with 
QOL. Spasticity may affect physical components 
of QOL, and daily activities may be impacted in 
as many as 44% of patients with MS. Pain, occur-
ring in up to 86% of patients with MS, impacts 
daily function and QOL across the range of 
physical and mental domains. The contribution 
of these impairments and symptoms to the eco-
nomic burden has been less well characterized, 
although the importance of mobility to employ-
ment and productivity has been suggested by 
several studies. Conclusions: Evidence suggests 
that impaired mobility and symptoms such 
as fatigue, pain, depression, and spasticity are 
important contributory factors to the observed 
reduction in QOL, and in some cases, increased 
costs, associated with MS. There is a need for 
greater recognition of the presence and effects 
of these disabilities, and effective targeted treat-
ment options for specific impairments, poten-
tially resulting in improved QOL and reduced 
indirect costs.
Keywords: burden; costs; depression; fatigue; 
impairment; mobility; multiple sclerosis; pain; 
quality of life; spasticity; walking
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INTRODUCTION
Multiple sclerosis (MS) is a chronic disease 
characterized by increasing disability result-
ing from central nervous system inflammation, 
progressive demyelination, and axonal loss. 
MS has a prevalence of approximately 135 per 
100,000 population in the US, which translates 
to approximately 400,000 individuals; and the 
global estimate is about 2.5 million.1 Disease-
modifying drugs (DMD) are the primary treat-
ment strategy in MS. These drugs are used to 
reduce relapse rate and slow disease progres-
sion, but they do not repair pre-existing neuro-
nal damage. However, data from the US suggest 
that 40% to 50% of individuals are not being 
treated with DMDs.2,3
Despite the need for managing the underly-
ing disease, it is being increasingly recognized 
that it is the multiple symptoms and impair-
ments often present in patients with MS includ-
ing walking impairment, weakness, fatigue, 
cognitive impairment, bladder and bowel dys-
function, depression, visual impairment, and 
pain, that contribute to the burden of disease.1,4 
This burden is manifested by reductions in 
patient functioning, ability to perform activ- 
ities of daily living, and quality of life (QOL), as 
well as increased healthcare resource utilization 
and costs.4 Addressing these problems is impor-
tant considering that many patients are not tak-
ing DMDs, and that even among those who do, 
the benefits of these drugs on symptoms and 
impairments have not been clearly established. 
Consequently, the treatment paradigm has 
shifted to include the implementation of a more 
comprehensive approach that encompasses the 
disease and the patient by targeting the specific 
issues affecting patient function and QOL.5-8 This 
is especially important when considering that 
patients with MS and their treating physicians 
may not necessarily agree on which dimensions 
of health are most important. Some physicians 
generally consider the physical manifestations of 
the disease, whereas patients often place a high 
emphasis on vitality, general health, and men-
tal health.9 Lower health status and QOL have 
been reported in individuals with MS relative 
to general population norms, age- and gender-
matched controls, and individuals with other 
prevalent chronic conditions.10-17 Reduced QOL 
is consistent regardless of the instrument used 
including the Medical Outcomes Survey 36-item 
Short Form (SF-36)10-12 and 12-item Short Form 
(SF-12),13 the EuroQol 5D (EQ-5D),14-16 and the 
Health Utilities Index Mark 3 (HUI3).17
Progression of disease and associated dis- 
abilities resulting from dysfunction of the pyra- 
midal, cerebellar, visual, and other functional 
systems has traditionally been assessed using 
the disease-specific Expanded Disability Status 
Scale (EDSS).18 The EDSS ranges from 0, rep-
resenting a normal neurologic exam, to 10, 
representing death due to MS. Staging of dis- 
ability by the EDSS is weighted toward walk-
ing impairment in the middle range of the scale 
(4.5 to 7.5), and an individual with a score ≤3.5 
is considered to be fully ambulatory. However, 
objective walking, gait, and balance impairment 
have been observed in patients with EDSS scores 
<3,19,20 and even at what are considered low 
overall disability levels (between 1 and 3.5) sub-
stantial proportions of patients report walking 
difficulties (22%), cognitive dysfunction (38%), 
and fatigue (60%).21
Due to its early onset, often within the third 
or fourth decade of life and progressing through 
the most productive years,22 MS is associated with 
a high socioeconomic burden. The total average 
annual costs in the US have been conservatively 
estimated at $47,215,15 with indirect costs con-
sistently shown to be the predominant driver 
of the economic burden.15,23-26 Proportionately, 
lost productivity represents the single highest 
Adv Ther (2009) 26(12):1043-1057. 1045
component cost (44%), and while the cost of 
individual DMDs used to treat MS is high, the 
component cost of these drugs represents only 
22% of MS costs (Figure 1).15
Few studies have specifi cally focused on the 
contribution of individual impairments to the 
patient burden (ie, QOL). Additionally, their 
contribution to the economic burden has been 
explored to a lesser extent than their effects on 
QOL, since incremental costs related to symp-
toms are diffi cult to quantify. However, some 
data are available from broader studies of the 
impact of MS on socioeconomic burden, and 
these data may help characterize the contri-
bution of symptoms to the burden of MS. 
Therefore, the purpose of this article is to review 
the contribution of symptoms and impairments 
frequently occurring in patients with MS to QOL 
and costs.
METHODS
Although this was not a systematic review, 
studies for inclusion were chosen from the litera-
ture that reported on QOL and costs in patients 
with MS, identifi ed from PubMed searches for 
articles published up until January 31, 2009. The 
main search terms were “multiple sclerosis” com-
bined with “quality of life,” “costs,” or “burden” 
with the limitation of English language publica-
tions. Selection of articles was based on whether 
the analyses included evaluation of specific 
symptoms and impairments as contributory fac-
tors to QOL or costs. Reference lists of the ident-
ifi ed articles were additionally hand-searched 
for potential studies that may have been missed 
using the original search criteria.
The selected articles relied on a variety of 
instruments to measure health status and QOL 
outcomes. Although most of the instruments 
are generic rather than disease specific, they 
are widely used and accepted for assessing QOL 
across a range of disease states and conditions. 
These instruments included the SF-36 and the 
shorter SF-12. The former is the most widely 
used generic instrument for evaluating health 
status and QOL, and consists of eight domains 
(physical functioning, role-physical, bodily 
pain, general health, vitality, social function-
ing, role-emotional, and mental health) as well 
as physical and mental component summary 
scores,27 while the latter is a 12-item version of 
Figure 1. Distribution of components contributing to the economic burden of multiple sclerosis in the US, adjusted for an 
estimated national average use of 52% for disease-modifying drugs. Reprinted with permission from Kobelt G et al. Costs 
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the SF-36 that measures the same domains.28 The 
SF-36 was also the basis for the disease-specific 
54-item Multiple Sclerosis Quality of Life instru-
ment (MSQOL-54), which incorporates items 
of relevance to patients with MS such as bowel 
and bladder function, sexual function, cogni-
tive function, and health distress.29 Other instru-
ments used in the studies reviewed here were the 
HUI3, a generic multiattribute health status class- 
ification system that characterizes health states 
based on functional capacity defined by eight 
attributes (vision, hearing, speech, ambulation, 
dexterity, emotion, cognition, and pain and 
discomfort),30 and the EQ-5D. The EQ-5D is a 
patient preference-based instrument consisting of 
five items that assess the level of difficulty (none, 
some/moderate, extreme) respondents report for 
the health status domains of mobility, self-care, 
usual activities, pain/discomfort, and anxiety/
depression.31 Also used, although less frequently, 
is the World Health Organization Quality of Life-
Brief Version (WHOQOL-BREF), an instrument 
that consists of 26 items that measure the broad 
domains of physical health, psychological health, 
social relationships, and environment.32
When considering the data reviewed here, it 
should be borne in mind that it is difficult to 
evaluate individual symptoms and impairments 
since there are often interactions between them, 
such that a specific symptom or impairment may 
overlap with others such as fatigue and depres-
sion, and mobility and spasticity.
IMPACT OF SYMPTOMS AND 
IMPAIRMENTS ON HEALTH-
RELATED QOL
Mobility impairment is one of the most 
well-recognized characteristics of MS, and has 
been reported in up to 90% of individuals.10,33,34 
Among individuals treated with DMDs, only 
52% reported some improvement in mobility.10 
According to the World Health Organization 
International Classification of Functioning, 
Disability and Health (ICF), mobility and walk-
ing are distinctly defined: mobility is mov-
ing by changing body position or location or 
by transferring from one place to another, by 
carrying, moving or manipulating objects, by 
walking, running or climbing, and by using vari- 
ous forms of transportation; walking is moving 
along a surface on foot, step by step, so that one 
foot is always on the ground, such as when stroll-
ing, sauntering, walking forwards, backwards, or 
sideways.35 The progressive worsening of walk-
ing results in the need for assistive devices, and 
estimates from a longitudinal study suggest that 
by 15 years after diagnosis, there is an approx- 
imate 40% probability for needing some form of 
walking assistance and a 25% probability for use 
of a wheelchair.36
Impaired mobility, especially related to walk-
ing ability, impacts functional activity and inde-
pendence. Gait parameters including walking 
speed and stride length have been reported to be 
significant predictors of patient dependence in 
activities of daily living (P<0.05).37 It is therefore 
not surprising that mobility impairment was 
ranked high among patient concerns.38,39 In a 
survey conducted in the US, mobility was given 
the highest priority by 65% of patients among 
factors affecting QOL.38 Similarly, in patients 
with MS duration <5 years and >15 years, walk-
ing was ranked first among 13 bodily functions 
by the greatest proportion of patients regard-
less of level of disability and disease duration; 
approximately 37% and 28% of those with dura-
tion <5 years and >15 years, respectively.39
Using the EQ-5D, Hemmett et al.10 reported 
that of the five dimensions (mobility, self-care, 
usual activities, pain/discomfort, depression/ 
anxiety), walking was the dimension with the 
highest proportion of patients reporting dif-
ficulties (89.5%), paralleled by usual activities 
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(89.2%)—a dimension that may be considered to 
be mobility-related since it encompasses work, 
housework, and family and leisure activities.10 
However, Gottberg et al.14 reported that the pro-
portion of patients reporting mobility problems 
(67%), was second to the proportion reporting 
pain (69%), a difference from the former study 
that may be ascribed in part to the greater pro-
portion of patients with progressive disease (58% 
vs. 35%) and by a longer mean disease duration 
(19 years vs. 13 years).
Similar to the EQ-5D, the HUI3 is a health 
utility index that characterizes health states 
defined by eight attributes (vision, hearing, 
speech, ambulation, dexterity, emotion, cog-
nition, and pain and discomfort). Analysis of 
scores from the HUI3, collected from individu-
als with and without MS as part of a Canadian 
cross-sectional population health survey, showed 
that the largest difference in individual attribute 
scores between individuals with and without MS 
was for ambulation (0.26; 95% CI=0.20-0.32) 
(Figure 2).17 In a study based on data from the 
Sonya Slifka Longitudinal MS Study, scores on 
the physical component summary of the SF-12 
were significantly worse among MS patients with 
difficulty walking relative to those without such 
difficulty (31.3 vs. 45.9; P<0.05).13 It should be 
noted that this study, with patients representing 
a broad range of disability levels across all regions 
of the US, provides a comprehensive list of symp-
toms and impairments and shows that patients 
with these impairments have significantly worse 
scores on the physical and mental component 
summary of the SF-12 relative to patients with-
out these impairments (Table 1).13 Some of these 
health problems, including symptoms such as 
fatigue, pain, and depression, affect QOL inde-
pendent of the overall disease impact.40
Fatigue is a major complaint among ind- 
ividuals with MS. Up to 95% of patients report 
fatigue,10,41,42 which is frequently severe43 and is 
cited among the worst symptoms by a major-
ity of patients (69%) regardless of neurologic 
impairment.41 Fatigue is subjective and multi-
dimensional, and is therefore difficult to evalu-
ate, especially in chronic, complex diseases such 
as MS.44 The vitality domain of the SF-36 can be 
considered a proxy for fatigue, and the scores on 
this domain are significantly lower among ind- 
ividuals with MS relative to general population 
norms.11,12,40,45,46 Additional evidence from several 
studies also supports fatigue as an independent 
predictor of QOL, and in some cases with effects 
on specific QOL components.40,47-51 In particular, 
significant effects on both the physical and men-
tal components of QOL were reported by Benedict 
et al. (P<0.001),50 and Merkelbach et al. (P values 
from <0.05 to <0.001),49 with the former using 
the MSQOL-54 and the latter using the SF-36. 
Figure 2. Mean scores, adjusted for age, sex, education, marital status, social assistance, and number of medical conditions 
other than multiple sclerosis (MS), on the Health Utility Index Mark 3 (HUI3) attributes among patients with MS and the 
general population. Scores are presented in order of the greatest difference between MS and the general population. *P<0.05 
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Table 1. Mean scores on physical component (PCS12) and mental component (MCS12) summary scales of the Medical 
Outcomes Survey 12-item Short Form (SF-12) among multiple sclerosis patients with and without specific symptomatic 
impairments. Reprinted with permission from Wu et al.13
n (%)a
PCS12 score MCS12 score

















































































































































































aWeighted percentages and means, unweighted numbers.
bEffect size=mean for “Yes,” minus mean for “No,” divided by 10.
All scores were significantly lower (P<0.05) for patients with the impairment except for the mental component summary  
for “difficulty walking.”
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The latter study also suggested that the effects 
of fatigue on physical QOL were independent of 
EDSS disability.
More detailed analysis of the relationship 
between fatigue and QOL reported significant 
effects on each domain of the SF-36,51 and in 
a study by Forbes et al.,40 although quantitative 
data were not provided for each domain, the 
authors reported that increasing fatigue sever-
ity resulted in incremental decreases in all SF-36 
domains except social function and general 
health. These results suggest a broad impact of 
fatigue on QOL.
In contrast to the above studies, Wynia et 
al.42 reported that fatigue had a very limited 
direct impact on QOL, with a significant effect 
only on the physical functioning domain of the 
SF-36 (P<0.05), and no effects on any domains 
of the WHOQOL-BREF. This discrepancy with 
other studies was ascribed to fatigue mediating 
its effects through other impairments, which the 
authors suggested were not adequately adjusted 
for in other studies. However, given the extent of 
the presence and severity of fatigue in individu-
als with MS, it is surprising that direct effects on 
domains such as vitality were not observed.
Several of the above studies also reported 
that depression was independently associated 
with impaired QOL.40,47,48,51 While a general 
finding was that depression is strongly predic-
tive of QOL,50,52 it has been specifically reported 
that the presence of depression resulted in sig-
nificantly poorer (P<0.05) health perception, 
role limitations due to emotional dysfunction, 
health distress, fatigue, sexual function, and 
emotional well-being.48 Data from Forbes et al.40 
suggested a potential association between sever-
ity of depression and specific QOL domains; 
incremental reductions in scores were observed 
with increasing depression severity for all SF-36 
domains except role physical and general health. 
Although Wynia et al.42 also suggested that 
depression affects all aspects of QOL, their results 
were not demonstrative of this, since depression 
was incorporated into the single variable of gen-
eral impairment of mental functions, which also 
included cognitive dysfunction and sleep.
Spasticity has been reported in up to 84% of 
patients with MS. Despite the high prevalence 
of spasticity and its recognized contribution to 
pain, difficulty in ambulation, poor gait and 
balance, decreased range of motion, and prob-
lems with hygiene, little is known about its 
specific impact on QOL.53 A study using data 
from the North American Research Committee 
On Multiple Sclerosis (NARCOMS) patient regis-
try observed a 17% to 39% decrease in the phys-
ical component score of the SF-36 with each 
advancing level of spasticity severity relative to 
individuals with no spasticity, although there 
appeared to be less of an effect on the mental 
component score (12% reduction even with 
severe spasticity).53 Since there was no adjust-
ment for other factors including disability level, 
which also appeared to increase with increas-
ing spasticity, it is unclear whether the effects of 
spasticity on QOL are independent or mediated 
through other variables. Nevertheless, the study 
also reported on a more pragmatic outcome of 
spasticity; spasticity affected daily activities on at 
least a frequent basis in 44% of individuals with 
MS, and prevented daily activities in 4% of ind- 
ividuals. Similarly, Wu et al.13 reported that com-
pared with patients without spasticity, patients 
who reported spasticity had significantly lower 
scores (P<0.05) on the physical and mental sum-
mary components of the SF-12 (Table 1).13
The prevalence of pain in patients with MS, 
which has been reported as being up to 86%,54 
is comparable to that of spasticity. Although 
pain can be under-recognized as a symptom of 
importance to MS patients in the clinical setting, 
several studies have shown that the presence of 
pain adversely impacts daily function and QOL 
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across a wide range of domains.40,55-61 Wynia et 
al.42 suggested that pain only impacts the phys-
ical domain of QOL, but other studies have con-
sistently reported broader effects; as pain severity 
increased, signifi cantly lower scores on all SF-36 
domains were reported among patients with pain 
relative to pain-free patients with lower scores 
(Figure 3).40,56 Pain was also found to correlate 
with mental health aspects of QOL, with sig-
nifi cant associations between pain severity and 
both depression (Spearman R=–0.27; P<0.001) 
and anxiety (Spearman R=–0.39; P<0.001).62 Not 
surprisingly, pain reduced patient independ-
ence by limiting participation in activities of 
daily living55,57 and interfered with daily func-
tions including work, sleep, and recreational and 
social activities, with at least moderate interfer-
ence on daily life reported by up to nearly half 
of patients with pain.58-61
As previously noted, it has been reported 
that the presence of other symptoms and 
impairments in patients with MS result in sig-
nifi cantly lower SF-12 scores (Table 1),13 but less 
information is available on the specifi c contri-
bution of these to the overall burden. Of these 
impairments, a study by Rao et al.63 assessed the 
contribution of cognitive dysfunction to prob-
lems in daily living. They found that relative 
to cognitively intact patients, those who were 
cognitively impaired engaged in fewer social and 
avocational activities, reported more sexual dys-
function, experienced greater diffi culty in per-
forming routine household tasks, and exhibited 
more mood disturbances.
Two studies by Nortvedt et al.64,65 are notable 
not only for their fi ndings that bladder, bowel, 
and sexual dysfunction result in signifi cantly 
lower QOL relative to patients without these 
problems, even after adjusting for EDSS disabil-
ity, but also for their observations that bladder 
and sexual dysfunction are present in substantial 
proportions of patients with low physical dis-
ability. Of individuals with EDSS scores ≤4, 53% 
and 44% had sexual dysfunction and bladder 
dysfunction, respectively.
ECONOMIC IMPACT OF MS 
SYMPTOMS AND IMPAIRMENTS
Lack of appropriate instruments and data-
bases make the contribution of specifi c symp-
toms and impairments to costs even more 
diffi cult to assess than for QOL. Nevertheless, 
some relationships can be inferred from avail-
able studies. A relationship between walking 
disability and costs may be imputed by the 
changes in costs associated with the change in 
EDSS scores that relate to the various levels of 
Figure 3. Mean scores (95% CI) on the 36-item Short Form (SF-36) quality of life instrument among multiple sclerosis 
(MS) patients with and without pain. Domains are: physical functioning (PF); role-physical (RP); bodily pain (BP); general 
health (GH); vitality (VT); social functioning (SF); role-emotional (SE); mental health (MH). *P<0.01. From Svensden KB 
et al. Sensory function and quality of life in patients with multiple sclerosis and pain. Pain. 2005;114:473-481. Th is fi gure 
has been reproduced with permission of the International Association for the Study of Pain® (IASP®). Th e fi gure may not be 
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mobility impairment. A review of studies that 
evaluated costs stratified by EDSS scores showed 
that moderate walking limitations (EDSS 4.0 to 
4.5) increased total costs by up to 3.8 times the 
cost of patients with low disability (total costs 
increased from $7969 at EDSS 1 to $30,348 at 
EDSS 4), and losing the ability to walk without 
aid (EDSS 6.5) increased costs up to 7.46-fold 
(total costs increased from $932 at EDSS 1 to 
$6952 at EDSS 6.5).66 Among patients with EDSS 
disability scores 4.0 to 6.0, characterized by some 
walking impairment up to the need for constant 
assistance, nonmedical costs represent a higher 
proportion of costs than at other disease levels, 
since more patients are at working age at these 
disability scores.15,24 Additionally, nonmedical 
costs rise more steeply at earlier disability levels 
than direct medical costs.66 These nonmedical 
costs are mainly in the form of lost product- 
ivity, which has been suggested to be the single 
highest contributor to the societal burden asso-
ciated with MS; although at high EDSS scores 
(EDSS 6.0 to 9.5), which are characterized by 
severe walking impairment and complete loss of 
mobility, informal care from family and friends 
accounted for a large percentage of the patients’ 
total out-of-pocket costs.15,24
Productivity is compromised in patients with 
MS, and impaired mobility in particular has been 
suggested to be an important factor contribut-
ing to lost productivity. In a study by Scheinberg 
et al.,67 53% of patients reported physical diffi-
culty as their primary reason for leaving their 
job. Edgley et al.68 more specifically reported that 
ambulation problems were the primary symp-
toms in patients who quit working because of 
MS; 41% cited impaired mobility, with fatigue 
the next most frequent symptom (39%). Using 
the need for assistive devices as a surrogate for 
impaired mobility, Kornblith et al.69 developed 
the Mobility Dysfunction Index to evaluate 
the impact of mobility on employment. Using 
this index and the statistical technique of path 
analysis for evaluating causal relationships, the 
authors concluded that mobility was a major 
determinant of employment status.
In a recent study by Julian et al.70 the 
NARCOMS patient registry was used to deter-
mine patient and disease characteristics that are 
associated with employment status. Patient data 
were evaluated cross-sectionally and prospect- 
ively over two assessment periods with a mean 
interval of 1.56±0.93 years. This study confirmed 
the importance of the role of mobility in employ-
ment among patients with MS. While worsening 
of overall symptoms was predictive of unem-
ployment, logistic regression analysis ident- 
ified two predominant factors as significant pre-
dictors for entering and leaving the workforce 
over time: mobility and hand function. Greater 
difficulty with mobility and hand function were 
significantly associated with becoming unem-
ployed, odds ratios of 1.20 (P<0.05) and 1.25 
(P<0.001), respectively. Conversely, reduced dif-
ficulty was predictive of re-entering the work-
force, odds ratios of 0.82 and 0.83, respectively 
(P<0.05). Cognitive dysfunction has also been 
identified as a factor that impacts productivity 
in MS, since it has shown to be associated with 
a lower likelihood of employment.63,70 However, 
none of the studies have provided a quantitative 
assessment of the lost productivity costs associ-
ated with these impairments.
Studies have documented the indirect costs of 
MS due to lost income, equipment and structural 
alterations to the home, and formal, paid and 
informal, unpaid care. In contrast, there are lim-
ited quantitative data on component costs that 
are encompassed by direct medical care.2 These 
component costs are related to the use of both 
medical (inpatient, outpatient, and emergency) 
and pharmacy services. Direct medical costs of 
treatment related to impairments were described 
for the year 2004 using an administrative claims 
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database.2 Identification of conditions and costs 
were based on the presence of International 
Classification of Disease, 9th Revision, Clinical 
Modification (ICD-9-CM) codes and Episode 
Treatment Groups, with the latter used to ident- 
ify and aggregate claims data for procedures and 
services relevant to the treatment of MS. When 
aggregated by clinical condition, patients with 
medical claims having ≥1 diagnosis code for 
the presence of specific conditions had a signif- 
icantly higher average cost of treatment relative 
to the cost of an average MS episode, which was 
not specified as disease exacerbation or progres-
sion, ($12,879±$18,583) (Table 2), although the 
standard deviations related to these costs were 
also very large, since one of the difficulties in 
characterizing healthcare costs is that they are 
generally nonparametric. While in this study, 
optic neuritis was associated with the highest 
costs, these costs were the most variable, and 
this impairment also had the lowest frequency. 
Costs related to abnormality of gait and spasms 
were approximately 60% higher than the cost 
of the average MS episode, and costs related to 
other conditions ranged from 8% for depression 
to 45% for fecal incontinence, which was also 
higher than an average MS episode.
Pain also adds to the economic impact of 
MS, resulting from excess healthcare resource 
utilization and reduced employment among 
MS patients with pain relative to those with-
out pain.57,61,71 The direct costs associated 
with MS-associated pain were estimated in a 
Canadian study; the mean cost was reported to 
be Canadian $2528±$5695, and the median cost 
was $753 (interquartile range $209 to $2061). 
This apparent disparity in costs is likely due to 
the fact that resource utilization and its associ-
ated costs generally have a nonparametric dis-
tribution. Regardless of whether the median 
Table 2. Total average annual cost of multiple sclerosis (MS) with selected comorbid conditions presented in order of 
decreasing costs and compared with the cost of the average MS episode ($12,879). Reprinted with permission from Prescott 
et al.2
Condition (ICD-9-CM code)a n (% of total)b Average annual cost (SD), $ P valuec
Optic neuritis (341.0) 37 (0.4) 39,247 (138,557) <0.001
Abnormality of gait (781.2) 744 (7.4) 20,871 (37,948) <0.001
Spasms (781.0) 333 (3.3) 20,376 (26,652) <0.001
Fecal incontinence (787.6) 40 (0.4) 18,694 (14,101) 0.047
Urinary incontinence (788.3) 558 (5.5) 16,898 (19,118) <0.001
Voice disturbances (784.4, 784.5) 165 (1.6) 16,463 (25,537) 0.012
Ataxia (781.3) 311 (3.1) 16,168 (19,317) 0.002
Convulsions (780.3) 349 (3.5) 15,664 (20,381) 0.004
Malaise and fatigue (780.7) 2177 (21.6) 14,604 (17,630) <0.001
Depression (ETGs 95 or 96) 2001 (19.8) 13,928 (14,757) 0.005
Trigeminal neuralgia (350.1) 92 (0.9) 12,467 (17,494) 0.831
Burning, numbness, tingling sensations (782.0) 1738 (17.2) 12,504 (14,913) 0.356
Fibromyalgia/myalgia and myositis (729.1) 744 (7.4) 11,478 (12,574) 0.033
aThe prevalence of selected conditions was based on the presence of listed Episode Treatment Groups (ETGs), or one or more 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes present on medical claims 
any time during the study period.
bTotal n=10,099.
cP values calculated using analysis of variance for comparison with cost of the average MS episode.
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or mean cost is considered, the primary cost 
driver was the use of pain therapies.71 However, 
it should also be noted that Canada permits a 
wider range of options that may be used for the 
treatment of pain including use of cannabinoids; 
25% of patients in the study reported use of mar-
ijuana. Interestingly, the presence and severity 
of pain was not related to EDSS disability scores. 
Furthermore, the authors also reported that 
indirect costs resulting from lost work or leisure 
time due to pain were Canadian $669±$875 
(median $264, interquartile range $1 to $933), 
and that total costs correlated with levels of 
self-reported pain.71 Direct and indirect costs 
associated with other symptoms or MS-related 
disabilities have not been estimated.
As previously mentioned, QOL is substan-
tially affected by MS, and while it may be impor-
tant to account for the economic impact of QOL 
in health economic analyses, QOL is considered 
an intangible cost and is frequently not calc- 
ulated in burden-of-illness studies due to the 
difficulty of placing a monetary value on it. 
Nevertheless, one approach that can be used to 
estimate the monetary cost for changes in QOL 
is based on a traditionally accepted value of the 
willingness to pay for a quality-adjusted life-year 
(QALY). Using accepted values of US$60,000 
and €50,000 for a QALY, Kobelt et al. calculated 
that reduced QOL adds another $15,315 to the 
annual MS-associated costs per individual in the 
US,15 and €13,400 in the European Union.24
A more detailed analysis of the costs associ-
ated with reduced QOL, performed in a country-
specific setting (Spain), stratified cost per QALY 
by EDSS scores (0, 1.0 to 3.0, 3.5 to 5.5, 6.0 to 
7.0, 7.5 to 9.5) (Figure 4).72 Costs increased as 
EDSS disability levels increased, with the greatest 
increase in costs occurring at the EDSS boundary 
between EDSS intervals of 1.0 to 3.0 and 3.5 to 
5.5. It should be noted that scores higher than 
3.5 are characterized by a substantial reduction 
in mobility. These data also suggest that the 
greatest change in QOL and costs related to QOL 
occur early in the disease, with only increm- 
ental changes at higher levels of EDSS-rated 
disability. However, the costs associated with 
symptom-specific reductions in QOL have not 
been evaluated.
CONCLUSION
Increasing evidence suggests that the sub-
stantial socioeconomic burden associated with 
MS may arise from impairments and symptoms 
that may not be adequately reflected by concepts 
relating to level of disability. Even at low dis-
ability levels, patients place a high emphasis on 
mobility and other symptoms that affect their 
general and mental health as well as their overall 
QOL. However, physicians may be more focused 
on relapse rate reduction and slowing disease 
progression. Since some of the symptoms may 
be independent of disease course, further invest- 
igation of the contribution of these impairments 
to the burden of MS is warranted. Additionally, 
there is not only a need to establish the rela-
tionships among the symptoms and their con-
tributions to the overall reduction with regard to 
the effects of these impairments on employment 
Figure 4. Intangible costs (Euros; €) per multiple sclerosis 
(MS) patient per year according to level of disability on the 
Expanded Disability Status Scale (EDSS) score based on 
a value of €55,000 per quality-adjusted life-year (QALY). 
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and productivity; importantly, there is also a 
need for consistent vigilance for the effects of 
these disabilities, and optimizing treatment regi-
mens that target specific impairments. Effective 
intervention can ultimately decrease healthcare 
costs while improving patient QOL.
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